

IBD-related Malignancies Observed in 2015–2019

4 Years' Results from the Prospective, Nationwide Hungarian Registry IBD-related Malignancies – Hungarian Registry

Ágnes Milassin MD¹, Mariann Rutka MD¹, Mónika Szűcs MD², Klaudia Farkas MD¹, Mark Marcus MD¹, Renáta Bor MD¹, Kata Judit Szántó MD¹, Ferenc Nagy MD¹, Zoltán Szepes MD¹, László Lakatos MD³, Zsuzsanna Erdélyi MD³, László Szegedi MD⁴, Eszter Schäfer MD⁵, Attila Zaránd MD⁶, Anna Fábián MD¹, Anita Bálint MD¹, Tamás Molnár MD¹

¹Department of Medicine, University of Szeged, Albert Szent-Györgyi Faculty of Medicine and Health Center, Hungary;

²Department of Medical Physics and Informatics, University of Szeged, Albert Szent-Györgyi Medical School, Faculty of Science and Informatics, Hungary; ³Department of Internal Medicine, Csolnoky Ferenc Regional Hospital, Veszprém, Hungary; ⁴First Department of Internal Medicine, András Jóna Teaching Hospital, Nyíregyháza, Hungary; ⁵Military Hospital Medical Center, Hungarian Defense Forces, Budapest, Hungary; ⁶First Department of Surgery, Semmelweis University, Budapest, Hungary

Correspondence: milagn422@hotmail.com

Introduction: Patients with inflammatory bowel disease (IBD) have an increased risk to develop malignant neoplasms. Neither the exact mechanism, nor the frequency of different malignancies is completely clear. Our aim was to assess the IBD associated malignancies, to collect clinical and mortality data and to analyse possible risk factors.

Methods: Data on malignancies developed between January 2015 and May 2019 in Hungarian IBD patients was recorded. Every member of the Hungarian Society of Gastroenterology was prospectively interviewed. The following data were collected: demographic data, disease characteristics, previous therapy, patient adherence, type and localisation of malignancies.

Results: 140 IBD patients with newly diagnosed malignancies were reported. 61.4%, 35.7%, and 2.9% of the patients had ulcerative colitis (UC), Crohn's disease (CD) and indeterminate colitis, respectively. The mean latency was 15.2±10.5 years. Colorectal cancer (CRC) was the most common cancer (49.6%, 70). 72.9% (51/70) of them was associated with UC, more than 80% had extensive (50.9%, 26) and left-sided (31.2%, 16) colitis. The most frequent CRC localisation was the rectosigmoid colon in UC (54.9%), and the rectum in CD (38.9%). The most common non-CRC malignancies were non-melanotic skin-cancer, haematological and pulmonary cancer. Disease duration at the time of the diagnosis of malignancy was lower (17.9±10.7 versus 12.6±9.7 years); mean age at the time of the death was higher (49.3±9.4 versus 64.3±16.4 years); and survival was longer after the diagnosis of extraintestinal malignancy than CRC (0.73±1.01 versus 1.2±0.8).

Summary: CRC presented typically in the distal part of the colon by male UC patients with pancolitis or left-sided colitis with a long-standing disease course of IBD. The most common non-CRC malignancies were non-melanotic skin cancer, haematological cancer and lung cancer. Non-CRC malignancies developed typically in female patients, older than CRC patients with shorter disease-course of IBD and longer survival times.

KEYWORDS: inflammatory bowel disease, colorectal cancer, malignancy, prospective

IBD-vel összefüggésben megfigyelt daganatos megbetegedések 2015–2019 között – Az IBD-vel kapcsolatos rosszindulatú daganatos megbetegedések prospektív, országos regiszterének 4 éves eredményei – Magyar Regiszter

Bevezetés: A gyulladós bélbetegségben (IBD) szenvedő betegeknél fokozott a rosszindulatú daganatok kialakulásának kockázata. Sem a pontos mechanizmus, sem a különböző malignitások gyakorisága nem teljesen tisztázott. Célunk az IBD-vel összefüggő rosszindulatú daganatok felmérése, klinikai és halálozási adatok gyűjtése, valamint a lehetséges kockázati tényezők elemzése volt.

Módszerek: A 2015 januárja és 2019 májusa között, magyar IBD-s betegeknél kialakult rosszindulatú daganatok adatait rögzítettük. A Magyar Gasztroenterológiai Társaság minden tagját prospektív módon kérdeztük. A következő adatokat gyűjtöttük: demográfiai adatok, betegségjellemzők, korábbi terápia, betegadherencia, a malignitások típusa és lokalizációja.

Eredmények: 140 IBD-s betegről számoltak be, akiknél újonnan diagnosztizált rosszindulatú daganatot állapítottak meg. A betegek 61,4%-a colitis ulcerosában (UC), 35,7%-a Crohn-betegségben (CD), 2,9%-a pedig indeterminált colitisben szenvedett. Az átlagos latenciaidő 15,2±10,5 év volt. A vastagbélrák (CRC) volt a leggyakoribb daganatos megbetegedés (49,6%, 70). Ezek 72,9%-a (51/70) UC-vel társult, több mint 80%-uknak kiterjedt (50,9%, 26) és bal oldali (31,2%, 16) colitise volt. A leggyakoribb CRC-lokalizáció UC-ben a rectosigmoid colon (54,9%), CD-ben a végbél (38,9%) volt.

A leggyakoribb nem-CRC rosszindulatú daganatok a nem melanotikus bőrrák, hematológiai daganatok és a tüdőrák voltak. Az extraintesztinális daganatok megjelenésénél a betegség átlagos fennállása rövidebb volt (17,9±10,7 versus 12,6±9,7 év), az átlagos életkor a halál idejében magasabb volt (49,3±9,4 versus 64,3±16,4 év), és a túlélés hosszabb volt (0,73±1,01 versus 1,2±0,8 év) mint colorectalis rák esetében.

Összefoglalva: A CRC jellemzően a vastagbél disztális részében jelent meg colitis ulcerosás férfi betegeknél, pancolitis vagy bal oldali colitis ulcerosa esetén, hosszabb betegségfennállás után. A leggyakoribb nem CRC rosszindulatú daganatok a nem melanotikus bőrrák, hematológiai daganatok és a tüdőrák voltak. A nem CRC daganatok gyakoribbak voltak a nőbetegeknél, idősebb életkorban jelentkeztek, mint a CRC, rövidebb betegségfennállás után, és hosszabb túlélés jellemezte.

KULCSSZAVAK: gyulladós bélbetegség, vastagbélrák, daganatos megbetegedés, prospektív

Introduction


Ulcerative colitis (UC) and Crohn's disease (CD) are life-long diseases with a chronic inflammation of the gastrointestinal (GI) tract. Patients with inflammatory bowel disease (IBD) have an increased risk to develop malignant neoplasms, particularly colorectal cancer (CRC) in ulcerative colitis and colon Crohn's disease because of the chronic intestinal inflammation, however recent studies suggest the rate is decreasing thanks to improved surveillance (1–7). Colorectal cancer is the third most common cancer worldwide and accounts for 10–15% of all deaths in IBD (8). IBD specific risk factors for CRC are ulcerative colitis and colon Crohn's disease, longer duration of IBD (8 years or more after diagnosis), extensive colon inflammation and coexisting primary sclerosing cholangitis (PSC), while male gender, increasing age and positive family history of CRC are risk factors to sporadic CRCs (9–11). Recently published data suggest that the risk of extraintestinal malignancies is also increased in IBD patients (12, 13). Disease-, patients- and therapy-related causes are taken into consideration; however, neither the exact mechanism, nor the frequencies of different malignancies are completely clear. CD patients are more likely to develop extraintestinal malignancies than UC patients. Upper GI cancer, lung cancer, urinary bladder cancer, skin squamous cell cancer, breast cancer were more frequent among CD patients and liver-biliary cancer, leukaemia, breast cancer and corpus uteri cancer among UC patients (5, 13, 14).

Due to the chronic nature of IBD, the impact of frequently used therapy in cancer development is still the subject of intensive debate. Thiopurine use can increase the risk of cancer, especially for lymphoma, haematologic cancer, skin squamous cell cancer (15–17). The currently available meta-analyses suggest that the overall risk of cancer is not increased in patients treated with anti-TNF-alpha therapy alone (18, 19). Our aim in this prospective, nation-wide study was to assess the IBD associated malignancies, to collect clinical and mortality data and to analyse possible risk factors.

Methods

Data on malignancies developed between January 2015 and May 2019 in Hungarian IBD patients was recorded. Every member of the Hungarian Society of Gastroenterology was prospectively interviewed every 6 months by personal e-mail to report malignancies observed in their patient population. The following data was collected in Excel-spreadsheets: IBD-related data: demographic data including gender, age at the time of the diagnosis of IBD, disease characteristics, such as type and nature of IBD, previous immunosuppressive or biological therapy, patient adherence; malignancy related data: age at the time of the diagnosis of malignancy, localisation, TNM stage of the tumour and in case of colorectal cancer the year of the previous colonoscopy. In the end of May 2019 all physicians were interviewed about the previously reported patients' status. Patients were eligible for the study if they had inflammatory bowel disease before or at the time of the di-

Fig. 1. Distribution of malignancies in inflammatory bowel disease



agnosis of malignant cancer. All type of malignant cancers was taken into account. The stage of colorectal cancer was based on the 8th Edition TNM Staging system.

A descriptive statistical analysis was performed. Statistical data was reported as the mean ± SD (standard deviation); with frequencies (n) and percentages (%), when appropriate, for the survival time mean ± SE (standard error) were calculated. Pearson's chi-squared test or Fisher's exact test was used to analyse categorical data, whereas independent samples t-test was used in case of continuous data.

Table 1. Demographic data of patients suffering from colorectal cancer (CRC) and non-colorectal cancer (non-CRC)

	CRC patients (N=70)	non-CRC patients (N=71)	P value
Type of disease (N, %)			0.015*
• Ulcerative colitis	51 (72.9%)	35 (49.3%)	
• Crohn's disease	18 (25.7%)	33 (46.5%)	
• Indeterminate colitis	1 (1.4%)	3 (4.2%)	
Gender (N, %)			0.090
• Male	50 (71.4%)	30 (42.3%)	
• Female	20 (28.6%)	41 (57.7%)	
Age at the time of diagnosis of IBD (mean ± SD, years)	33.9±16.7	42.2±18.4	0.010*
Age at the time of diagnosis of malignancy (mean ± SD, years)	51.4±13.7	54.8±5.8	0.274
Disease duration at the time of diagnosis of malignancy (mean ± SD, years)	17.9±10.7	12.6±9.7	0.001*
Age at the time of death (mean ± SD, years)	49.3±9.4 ⁺	64.25±16.4 ⁺⁺	0.011*
Survival time after the diagnosis of malignancy (mean ± SE, years)	0.73±1.01 ⁺	1.19±0.83 ⁺⁺	0.208

*P<0.05 was considered significant, ⁺N=11 patients, ⁺⁺N=16 patients

The survival probabilities were estimated by Kaplan-Meier analysis. The differences in the survival of the CRC and non-CRC groups were examined by a log-rank test. Statistical tests were performed using R statistical software (R version 3.6.2, <https://www.r-project.org/>), values of P<0.05 were considered significant.

The study was approved by the Ethical Committee (3929, 15/2017-SZTE). The data are collected and analysed anonymously.

Results

Demographic data

140 IBD patients were reported by the members of the HSG. Patients were reported from 20 departments, altogether from 11 cities (Békéscsaba, Budapest, Debrecen, Gyula, Nyíregyháza, Pápa, Pécs, Szeged, Szekszárd, Szombathely, Veszprém). The majority of patients were male (female:male ratio was 35:65%; 49:91 patients). 61.4%, 35.7%, and 2.9% of the patients had UC, CD and indeterminate colitis (IC), respectively. The mean age of the patients at the time of initial diagnosis of malignancy was 53.0±14.7 (range 14-92) years. At the time of initial diagnosis of IBD, the mean age was 38.0±18.0 (range 8-86) years. The mean latency between the diagnosis of IBD and malignancy was 15.2±10.5 (range 0-52) years. Altogether 141 malignancies were reported – one patient had simultaneously two different types of tumour (descending colon and kidney), we counted it as two cases in the subgroup analyses.

Occurrence of malignancies

According to our results CRC was the most common cancer type (49.6%, 70), while the most common non-CRC malignancies were non-melanotic skin-cancer (5.7%, 8), haematological and pulmonary cancer (5.7-5.7%, 8-8) (Fig. 1.). The

Table 2. Demographic data of inflammatory bowel disease patients suffering from colorectal cancer. *(descending, transverse, ascending colon and coecum)

	Ulcerative colitis (N=51, 72.9%)	Crohn's disease (N=18, 25.7%)	Indeterminate colitis (N=1, 1.4%)
Localisation of the disease, N (%)	E1: 4 (7.8%) E2: 16 (31.4%) E3: 31 (60.8%)	L1: 4 (22.2%) L2: 6 (33.3%) L3: 8 (44.5%)	
Behaviour of the disease, N (%)		B1: 10 (55.5%) B2: 5 (27.8%) B3: 3 (16.7%)	
Gender, N (%)			
• Female	10 (19.6%)	10 (66.6%)	0 (0.0%)
• Male	41 (80.4%)	8 (44.4%)	1 (100.0%)
CRC localisation, N (%) (P=0.670)			
• Rectosigmoid colon	E1: 4 E2: 10 E3: 13	L1: 1 L2: 3 L3: 5	
• Colonic *	21 (41.2%) E1: 0 E2: 7 E3: 14	9 (50.0%) L1: 4 L2: 3 L3: 2	0 (0.0%)
• Multiplex	3 (5.9%) E1: 0 E2: 1 E3: 2	0 (0.0%)	0 (0.0%)


proportion of UC patients is significantly higher in the CRC subgroup contrary to the non-CRC subgroup (P=0.015). CRC patients were significantly younger at the time of diagnosis of IBD (P=0.01), had a longer disease duration before the diagnosis of malignancy (P=0.001) and died younger (P=0.011) contrary to non-CRC patients. There was no statistical difference in gender and the age at the time of diagnosis of malignancy. Table 1. shows the demographic data of the CRC and non-CRC patients in detail.

Colorectal cancer

As CRC can be a result of long-term IBD, it was analysed in detail. 70 patients were diagnosed with CRC. 72.9% (51 of 70) of CRC cases was associated with ulcerative colitis, more than 80% of them had extensive (50.9%, 26) and left-sided (31.2%, 16) colitis. Among CD patients ileocolonic and colonic localisation was observed in 44.4% (8/18) and 33.3% (6/18). In UC patients a male dominance was seen (80.4%). The mean age at the time of diagnosis of malignancy was 51.4±13.7 years. Mean disease duration of IBD was 17.9±10.7 years, but it was less than 8 years in 10 patients (70% of them had early stage CRC). In 5 cases CRC diagnosis was simultaneous with the diagnosis of IBD. Demographic data is detailed in Table 2. 27 patients (38.6%) had previous colonoscopies before the diagnosis of CRC, a mean 3.85±3.2 years. 21.4% (15 patients) of the patients were non-adherent to regular check-ups. Family history was positive to CRC in 15.7% (11 patients).

The most common CRC localisation in UC patients was the rectosigmoid colon (52.9%, 27), and the rectum in CD patients (38.9%, 7) (Figure 2.). There was no statistical difference between the tumour localisation and the nature of the disease. Three patients had multiplex tumours: one ulcerative colitis (E2) patient had simultaneous adenocarcinoma in coecum and rectum; the second ulcerative colitis patient (E3) had three adenocarcinomas in coecum, descending colon and rectum; the third ulcerative colitis patient (E3), had four adenocarcinomas in colon and one in rectum. Tumour locali-

Fig. 2. Localisations of colorectal cancer in inflammatory bowel disease




sation of UC and CD patients is detailed in Fig. 2. Two patients had IBD-related operations previously where the malignancy developed: one UC patient had pouch adenocarcinoma, the other patient with Crohn's disease had adenocarcinoma in the ileotransverse anastomosis.

The nature of the disease was also evaluated. Chronic continuous symptoms, chronic remission, relapse and remission, relapse after chronic remission was observed in 37.1% (26), 24.3% (17), 20.0% (14) and 2.9% (2) of the patients, respectively (15.7%, 11 patients had no data available). Half of the patients with CD had non-stricturing, non-penetrating disease, 27.8% had stenotising and 16.7% had penetrating disease behaviour (5.5% had no data about the behaviour of the disease).

Only 28.7% (20 patients) of the malignancies were detected in early stage (Stage 0 or Stage 1). One (5%) of them died in pneumonia and sepsis in the year of the tumour diagnosis. Stage 2, Stage 3 and Stage 4 tumour was detected in 50 patients (71.3%), 10 (18%) of them died after a mean 0.55 year (Fig. 3.). There was no statistical difference in the previously used therapy (immunosuppressive, biological therapy or both) and the stage of the CRC.

At the time of the diagnosis of malignancy 71.4% (50) of the patients received aminosalicylates, 37.1% (26), 28.6% (20) received steroid and/or immunosuppressive therapy, and

Fig. 3. Stages of colorectal cancer at the time of the diagnosis of malignancy



only 11.4% (8) received biological therapy. Previously 42.9% (30) of the patients received immunosuppressive therapy a mean 63.3±58.1 months, 60% of them received azathioprine (AZA) alone, and 40% received a combination therapy.

Non-colorectal cancers

The most frequently observed non-CRC malignancies in our cohort were non-melanotic skin-cancer (5.7%, 8), haematological (5.7%, 8) and pulmonary cancer (5.7%, 8), then

Table 3. Summary of non-colorectal cancers

	Female:male	CD:UC:IC	Age at the time of diagnosis of IBD (mean ± SD)	Age at the time of diagnosis of malignancy (mean ± SD)	Disease duration (mean ± SD)	Previous immunosuppressive therapy	Previous biological therapy	Death
Non-melanotic skin cc. (N=8)	5:3	3:5:0	40.0±13.6	55.6±11.5	15.0±6.2	8/8	3/8	0/8
Lung cc. (N=8)	5:3	5:3:0	65.1±9.4	68.6±6.9	3.5±3.7	5/6	1/6	3/8
Haematological cc. (N=8)	0:8	5:3:0	44.5±25.6	51.9±20.8	7.4±6.5	5/8	4/8	1/8
Gynaecological cc. (N=7)	7:0	3:3:1	39.0±21.9	53.1±21.1	14.1±11.8	3/7	2/7	1/7
Prostate cc. (N=6)	0:6	0:5:1	53.0±11.9	67.3±7.2	14.2±10.9	1/6	1/6	1/6
Pancreas and biliary tract cc. (N=5)	3:2	2:3:0	31.6±17.6	51.0±17.8	19.4±10.5	3/5	2/5	4/5
Kidney cc. (N=4)	2:2	2:1:1	39.5±15.2	49.3±16.1	9.8±8.4	2/4	3/4	1/4
Malignant melanoma (N=3)	0:3	2:1:0	31.0±3.5	47.0±7.0	16.0±5.6	2/3	1/3	0/3
Breast cc. (N=3)	2:1	2:1:0	15.0±2.0	42.7±5.7	27.7±6.5	3/3	2/3	0/3
Liver cc. (N=3)	2:1	1:2:0	28.0±19.0	47.7±16.8	19.7±9.6	1/3	2/3	2/3
Upper GI cc. (N=3)	2:1	2:1:0	44.3±18.8	59.3±11.1	15.0±9.2	2/3	1/3	0/3
Oropharyngeal (N=3)	1:2	2:1:0	37.7±11.5	50.7±17.0	13.0±5.6	3/3	1/3	2/3
Urological cc. (N=2)	1:1	0:2:0	55.0±2.8	59.5±7.8	4.5±4.9	0/2	0/2	0/2
Neurological cc. (N=2)	1:1	1:1:0	29.5±21.9	29.5±21.9	0.0±0.0	1/2	1/2	0/2
Tonsil cc. (N=2)	2:0	1:1:0	46.0±7.1	50.5±4.9	4.5±2.1	1/2	1/2	0/2
Thyroid gland cc. (N=1)	0:1	1:0:0	36.0	36.0	0.0	1/1	0/1	0/1
Appendix cc. (N=1)	0:1	0:1:0	35.0	54.0	19.0	1/1	1/1	0/1
Sarcoma (N=1)	0:1	0:1:0	35.0	65.0	30.0	0/1	0/1	1/1

Cc. = cancer; GI = gastrointestinal; th = therapy

gynaecological and prostate malignancies in 5% and 4.3% (7 and 6 patients). Non-colorectal cancers are detailed in Table 3. Non-melanotic skin cancers (NMSC) were the following: 5 cases had basal cell carcinoma and 3 cases had squamous cell carcinoma. All of the patients with NMSC had previous immunosuppressive therapy for a mean 79.8±50.8 (12-144) months. IBD-related therapy of patients with skin cancer is detailed in Table 4.

8 patients had haematological malignancies, all of them were male. Three of them had ulcerative colitis with the following leukaemia: chronic myeloid leukaemia, acute myeloid leukaemia and chronic lymphoid leukaemia, and five of them had Crohn's disease with the following diseases: diffuse large B-cell lymphoma (2 cases), non-Hodgkin lymphoma, Waldenström macroglobulinemia and chronic myeloid leukaemia.


8 patients had lung cancer, 5 patients had Crohn's disease, 3 had ulcerative colitis. 7 patients had gynaecological malignancy. 6 patients had a prostate tumour, only one of them had long-term combination immunosuppressive treatment. Mean age at the time of diagnosis of prostate malignancy was 67.3 years (min: 54, max: 74); the 54 years old patient was that who had long term combination immunosuppressive treatment, all the other patients were over 65 years old.

IBD-related medical therapy was the following in the non-CRC subgroup: 76.1% (54) of the patients were on aminosalicylates, 15.5% (11) on steroids, 38.0% (27) on immunosuppressive therapy and 18.3% (13) on biological therapy at the time of the diagnosis of malignancy. Previously, 56.3% (40) received azathioprine (68.5±56.9 years): 23.9% (17) received azathioprine alone, 32.4% (23) received combination therapy and 5.6% (4) received biological therapy alone.

Comorbidities

Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) was analysed in detail. 10 cases were associated with PSC, from them 6 had CRC, 2 had liver malignancy and 2 patients had biliary adenocarcinoma. 2 patients with colorectal cancer had PBC. Mean age at the time of diagnosis of CRC in patients with PSC or PBC was lower contrary to patients without comorbidities (45.5±7.4 versus 52.2±14.2 years).

Fig. 4. Survival after the diagnosis of colorectal cancer and non-colorectal cancer



Survival

19.3% (27/140) patients died after the diagnosis of malignancy after a mean 1.0±0.92 years, 86% of the patients were adherent to regular check-ups. 15.7% (11 of 70) of CRC patients and 22.5% (16 of 71) of non-CRC patients died during the follow-up period. Male dominance was observed (19:8). CRC patients died significantly younger than non-CRC patients (49.3±9.4 versus 64.3±16.4 years). There was no statistical difference between the survival of CRC (8.44±0.434 years) and non-CRC (7.91±0.459 years) patients (P=0.458) (Fig. 4.) and the survival of early or late stage colorectal cancers (P=0.758).

Discussion

In our nationwide prospective study 140 IBD patients were reported with malignancy over a time course of 4 years (2015–2019).

Based on our findings the most common malignancies were colorectal cancers (49.6%), non-melanotic skin cancers (5.8%), haematological neoplasms (5.8%) and malignant neoplasms of the lung (5.8%). These data are in concordance with the recently published Hungarian

Table 4. IBD-related therapy of patients with skin cancer

	Squamous cell carcinoma (N=3)	Basal cell carcinoma (N=5)	Malignant melanoma (N=2)
Therapy at the time of diagnosis of malignancy			
• Aminosalicylate	3	5	2
• Steroid	0	0	0
• Immunosuppressive	3	3	2
• Biological therapy	1	0	1
Previously received therapy			
• Immunosuppressive	3	5	2
• Biological therapy	3	1	1

population-based data, where 8.5% of the incident UC population was diagnosed with CRC (20). Similar data were presented by a Danish population-based study from 1962 to 1987, where increased risk of colorectal cancer and melanoma was found in UC patients, but for other cancers they couldn't verify this (21). A Scandinavian population based-study also found an increased risk of developing CRC both in UC and CD patients (HR [hazard ratio]: 1.66 and 1.40) (2, 3). Other studies suggest that the risk of CRC is declining over time (1, 22, 23). A recently published Swiss IBD cohort study found controversial results concerning CRC: they found an increased risk for lymphoma and biliary cancer, but not for colorectal cancer (22).

Colorectal cancers were more frequent in UC patients and developed after a significantly longer disease duration contrary to non-CRC patients (17.9 versus 12.6 years). In UC patients with colorectal cancer a male dominance was seen. Non-CRC patients were older at the time of death (64.3 versus 49.3 years); and survival time was longer (1.2 versus 0.73 years) after the diagnosis of non-CRC malignancy than CRC. These findings are in concordance with the previously published findings, which showed that ulcerative colitis increases the risk of CRC and male gender, younger age at diagnosis of UC (disease duration), extensive colitis and geography were independent risk factors (9, 24).

Based on our results the most common CRC localisation in UC patients was the rectosigmoid part of the colon (54.9%), and the rectum in CD patients (38.9%). In line with our data, increased risk for CRC and hepatobiliary cancers among IBD patients was found, and rectal cancer was more frequent among UC patients (25), but not among CD patients (6). 85.7% of the patients had longstanding disease (17.9 years) in our cohort, it should be noted that it was less than 8 years in 10 patients (70% of them had early stage CRC), which can be a result of diagnostic delay. Primary sclerosing cholangitis can increase the risk of CRC in IBD patients, especially in ulcerative colitis patients (26). In our cohort IBD patients with PSC were younger at the time of CRC onset, contrary to patients with IBD alone.

Colorectal cancer stages in our cohort are in concordance with the findings of the Hungarian population-based colorectal cancer screening pilot study's result (27). In this pilot study stage 0 and 1 tumour was diagnosed in 26.7%, stage 2 in 27.2%, stage 3 in 22.6% and stage 4 in 23.5%, while in our cohort the data was 28.6%, 22.9%, 27.1% and 17.1%, respectively.

Non-CRC patients were predominantly female. The most common non-CRC malignancies were non-melanotic skin cancers, haematological neoplasms and malignant neoplasms of the lung. In our cohort all the patients with leukaemia suffered from UC. Although the overall risk of extra-intestinal malignancies is not increased in IBD, the individual cancer types depending on the background population, CD patients have an especially increased risk to develop cancers (10, 13, 28). Contrary to our results, some studies found increased risk of lymphoma in CD patients,

especially in males. This risk was independent of thiopurine use (6, 25, 28). Pedersen et al found an increased risk of cancer of the upper gastrointestinal tract (SIR [standardised incidence ratio]: 2.85), lung (SIR: 1.82), urinary bladder (SIR: 2.03) and skin (SIR: 2.35) among CD patients and of leukaemia (SIR: 2.0) and liver-biliary cancer (SIR: 2.58) among UC patients. A Spanish retrospective, multi-centre, 5-year follow up, observational study found an increased risk for non-melanoma skin-cancer and for small-bowel cancer (RR [relative risk] = 3.85 and 3.70) (23). This difference in the distribution of extraintestinal malignancies may be a result of different smoking habits and extra-intestinal manifestations (13).

All the patients with non-melanotic skin cancer was on longstanding immunosuppressive therapy for a mean 79.8 months. All the patients had squamous cell carcinoma and basal cell carcinoma, which is in range with previous study's results (13). Patients on thiopurine therapy has increased risk of non-melanoma skin cancer (12), haematologic cancer, non-Hodgkin lymphoma, skin squamous cell carcinoma and overall cancer (17).

This study has some limitations. However, this study was a prospective study there is still some incomplete data (medication, cancer stage, adherence). It could happen because not all the patients were initially diagnosed with IBD in the referral centre/physician, and some patients haven't returned to the referral physician during the study period. This database is not representative of the Hungarian population, since participation was voluntary. The CRC cases can be overestimated, due to the fact that patients with CRC visit gastroenterological centres more frequently, while patients with extraintestinal malignancies may be out of sight after the diagnosis of malignancy for years.

Conclusion

The most frequently observed IBD-related malignancy in our cohort was colorectal cancer. Colorectal cancer presented typically in the distal part of the colon by male ulcerative colitis patients with pancolitis or left-sided colitis with a long-standing disease course of IBD. The most common non-colorectal cancer malignancies were non-melanotic skin cancer, haematological cancer and lung cancer. Patients with non-colorectal cancer malignancies were typically female and older than colorectal cancer patients at the time of the diagnosis of malignancy had a shorter disease-course of IBD and a longer survival time.

Acknowledgments

We thank the participants of the Hungarian IBD Study Group – Ágota Kovács, Patrícia Sarlós, Márta Varga, András Gelley, Zsuzsanna Kürti, Péter Lakatos, Lilla Lakner, Károly Palatka, Tamás Szamosi, Áron Vincze, Mihály Balog, Zsolt Barta, Ákos Iliás, János Novák, Tünde Pandur, Nóra Szigeti, János Banai, Ildikó Kovács, Márta Kovács, Pál Miheller, Ágnes Salamon, Valéria Sipos, Gyula Tolvaj, Gábor Veres, Tibor Wittmann, Alexandra Zádori-Born, Edit Balla, Anita Gaál, Krisztián Pepa – for their active participation in the study.

Irodalom

1. Loo S, Vutcovici M, Bitton A, Lakatos P, Azoulay L, Suissa S, Brassard P. Risk of Malignant Cancers in Inflammatory Bowel Disease. *J Crohns Colitis*. 2019; 13(10): 1302–1310. <https://doi.org/10.1093/ecco-jcc/jjz058>.
2. Olén O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, Ekbohm A, Sørensen HT, Ludvigsson JF. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study. *Lancet Gastroenterol Hepatol*. 2020 May 1; 5(5): 475–484. [https://doi.org/10.1016/S2468-1253\(20\)30005-4](https://doi.org/10.1016/S2468-1253(20)30005-4).
3. Olén O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, Ekbohm A, Sørensen HT, Ludvigsson JF. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. *Lancet*. 2020 Jan 11; 395(10218): 123–131. [https://doi.org/10.1016/S0140-6736\(19\)32545-0](https://doi.org/10.1016/S0140-6736(19)32545-0).
4. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. *Inflamm Bowel Dis*. 2013; 19(4): 789–799. <https://doi.org/10.1097/MIB.0b013e31828029c0>.
5. Taborelli M, Sozzi M, Del Zotto S, Toffolutti F, Montico M, Zanier L, Serraino D. Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy. *PLoS One*. 2020 Jun 23; 15(6): e0235142. <https://doi.org/10.1371/journal.pone.0235142>
6. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The Risk of Cancer in Patients with Crohn's Disease. *Dis Colon Rectum*. 2007 Jun; 50(6): 839–855. <https://doi.org/10.1007/s10350-006-0848-z>.
7. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-Year Analysis of a Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis. *Gastroenterology*. 2006; 130(4): 1030–1038. <https://doi.org/10.1053/j.gastro.2005.12.035>
8. Herszényi L, Barabás L, Miheller P, Tulassay Z. Colorectal Cancer in Patients with Inflammatory Bowel Disease: The True Impact of the Risk. *Dig Dis*. 2015; 33(1): 52–57. <https://doi.org/10.1159/000368447>.
9. tients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies. *Clin Gastroenterol Hepatol*. 2012; 10(6): 639–645. <https://doi.org/10.1016/j.cgh.2012.01.010>.

10. Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferrri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. *Journal of Crohn's and Colitis*. 2015 Nov; 9(11): 945–965. <https://doi.org/10.1093/ecco-jcc/jjv141>.
11. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. Vol. 372, *New England Journal of Medicine*. 2015; 372: 1441–1452. <https://doi.org/10.1056/NEJMra1403718>
12. Chang M, Chang L, Chang HM, Chang F. Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease. *Clinical Colorectal Cancer*. 2018; 17(1): e29–37. <https://doi.org/10.1016/j.clcc.2017.06.009>
13. Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: Meta-analysis of population-based cohort studies. *Am J Gastroenterol*. 2010 Jul; 105(7): 1480–1487. <https://doi.org/10.1038/ajg.2009.760>.
14. Hovde Ø, Hoivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA. Malignancies in patients with inflammatory bowel disease: Results from 20 years of follow-up in the IBSEN study. *J Crohns Colitis*. 2017; 11(5): 571–577. <https://doi.org/10.1093/ecco-jcc/jjw193>.
15. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: A UK population-based case-control study. *Am J Gastroenterol*. 2010 Jul; 105(7): 1604–1609. <https://doi.org/10.1038/ajg.2009.745>.
16. Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. *Am J Epidemiol*. 2013 Jun 1; 177(11): 1296–1305. <https://doi.org/10.1093/aje/kws375>.
17. van den Heuvel TRA, Wintjens DSJ, Jeuring SFG, Wassink MHH, Romberg-Camps MJL, Oostenbrug LE, Sanduleanu S, Hameeteman WH, Zeegers MP, Masclee AA, Jonkers DM, Pierik MJ. Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort. *Int J Cancer*. 2016 Sep 15; 139(6): 1270–1280. <https://doi.org/10.1002/ijc.30183>.
18. Williams CJM, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: Malignancies with anti-tumour necrosis factor- α therapy in inflammatory bowel disease. Vol. 39, *Aliment Pharmacol Ther*. 2014. Mar; 39(5): 447–458. <https://doi.org/10.1111/apt.12624>.
The rest of the references can be found in the editorial office and on the website <http://www.gastronews.hu>.

Gelsectan® KAPSZULA

A BÉLFUNKCIÓ HELYREÁLLÍTÁSÁRA

Bioprotektív filmréteggel

Klinikailag igazoltan hatékony IBS-D esetében*

Goodwill 30 kapszula

Gelsectan® A BÉLFUNKCIÓ HELYREÁLLÍTÁSÁRA

Gyártó: DEVINTEC SAGL
Corso Elvezia 14
6900 Lugano, Svájc

CE 1370

Új fejezet A MUKOPROTEKCIÓBAN

A bélműködés helyreállítására:

- a krónikus vagy kiújuló hasmenés,
- haspuffadás, fájdalom és bélgázképződés enyhítésére vagy megelőzésére szolgál.

Irritábilis bél szindróma (IBS-D) okozta bélműködési rendellenességekben:

- bél túlérzékenység,
- bizonyos gyógyszerek szedése esetén.

*Trifan et al. *United European Gastroenterol J*. 2019 Oct; 7(8):1093-1101. Ciriza de Los Rios et al. *Therap Adv Gastroenterol*. 2021 May. Vol. 14. 1–10

Gelsectan® 30 db kapszula

Rendeltetés: A Gelsectan® kapszula a bélműködés helyreállítására és a krónikus vagy kiújuló hasmenés, haspuffadás, fájdalom, feltűvődés és bélgázképződés tüneteinek enyhítésére vagy megelőzésére szolgál olyan betegeknek, akik az irritábilis bél szindróma (IBS) okozta bélműködési rendellenességekben szenvednek, melyek összefüggésben állhatnak a bél túlérzékenységével vagy bizonyos gyógyszerek szedésével.

Összetétel: Xiloglükán, borsófehérje és szőlőmagkivonat, xilo-oligoszacharidok, magnézium-sztearát (növényi eredetű) és amorf lecsapott szilícium-dioxid.

Adagolás: A tünetek súlyosságától függően 1 vagy 2 kapszula naponta kétszer (reggeli és vacsora előtt) 2–4 héti. Szükség esetén a kezelés folytatható. Amennyiben termékünk alkalmazása során „nem kívánt eseményt” észlel, kérjük, 24 órán belül jelentse a pharmacovigilance@goodwillpharma.com e-mail címen vagy a +36 30 2222763 telefonszámon. Orvostechnikai eszköz. Dokumentum lezárva: 2021.11.15. GW02133



Goodwill Pharma Kft.
6724 Szeged, Cserzy Mihály u.32.
Tel: +36 62 443571

Goodwill